Danicopan

Introduction Overview

Generic Name

danicopan

Brand Name

Voydeya

Dosage Form

oral tablets

Drug Class

Selective immunosuppressants

Pharmacokinetics

Absorption:
Danicopan (Voydeya) is administered orally and exhibits good absorption in the gastrointestinal tract. The presence or absence of food does not markedly affect the bioavailability, allowing for flexible dosing with or without meals. Pharmacokinetic studies indicate that danicopan reaches peak plasma concentrations typically within a few hours post-dose, which supports the recommended thrice-daily dosing regimen. The drug's oral formulation as tablets allows for consistent systemic exposure necessary for effective complement factor D inhibition.

Distribution:
Once absorbed, danicopan distributes systemically, with plasma protein binding influencing its pharmacological activity and half-life. The distribution volume suggests moderate tissue penetration, sufficient for targeting complement factor D within the plasma and the alternative complement pathway. The selective targeting implies that danicopan remains predominantly within the vascular compartment and interstitial fluids, facilitating its action on circulating complement proteins.

Metabolism:
Danicopan undergoes hepatic metabolism primarily via cytochrome P450 enzymes, including CYP3A4 isoforms. This metabolism necessitates consideration of potential drug interactions with co-administered CYP3A4 inhibitors or inducers, which may alter plasma concentrations. The metabolic pathway results in inactive metabolites, which are then subject to elimination. The metabolism also contributes to the drug’s half-life, supporting multiple daily dosing for maintaining therapeutic plasma levels.

Elimination:
The elimination of danicopan occurs mainly via fecal excretion with a minor contribution from renal pathways. The half-life supports thrice daily administration to maintain effective plasma concentrations. In patients with severe hepatic impairment (Child-Pugh C), elimination may be significantly altered, increasing the risk for accumulation and toxicity; hence, the drug is contraindicated in this population. Renal function does not majorly influence elimination, but patients with compromised liver function require cautious use with monitoring of liver enzymes.

Dosage Forms

Available Dosage Forms:
- Oral tablets: 50 mg and 100 mg strengths.

Dosages for Adults and Adolescents:
- The recommended starting dose in adults is 150 mg taken three times daily.
- This is usually achieved by administering one 100 mg tablet plus one 50 mg tablet together, three times per day.
- Dose adjustment based on clinical response is permissible, with doses up to 200 mg three times daily achieved by taking two 100 mg tablets per dose.

Specific Patient Populations:
- Use in pediatric populations is not established; safety and efficacy have not been determined.
- Not recommended for patients with severe hepatic impairment (Child-Pugh C) due to altered pharmacokinetics and increased risk of toxicity.
- Dose adjustments or enhanced monitoring may be required in patients with underlying liver conditions or those concurrently receiving interacting medications.
- Given the risk of serious infections, patients should be vaccinated and enrolled in the REMS program prior to initiation.

Clinical Guidelines:
- Medication should be taken consistently at approximately equal intervals to maintain stable plasma drug levels.
- Voydeya can be taken with or without food to enhance patient adherence.
- Patients should not discontinue or alter dosing without consultation with healthcare providers due to the risk of hemolytic crises associated with discontinuation.

Mechanism Of Action

Danicopan (Voydeya) acts as a selective, potent inhibitor of complement factor D, a serine protease enzyme critical to the activation and amplification of the alternative complement pathway. Specifically, factor D cleaves complement factor B when bound to C3b to generate the C3 convertase (C3bBb), advancing the cascade that leads to membrane attack complex (MAC) formation and cell lysis.

By binding selectively to the active site of factor D, danicopan prevents its proteolytic activity, thereby interrupting the formation and stabilization of the C3 convertase enzyme complex. This suppresses the alternative pathway’s amplification loop, reducing the excessive complement activation observed in paroxysmal nocturnal hemoglobinuria (PNH).

Clinically, this mechanism mitigates extravascular hemolysis (EVH), a process whereby opsonized red blood cells are prematurely cleared by the spleen and liver. While C5 inhibitors like ravulizumab and eculizumab address intravascular hemolysis by blocking the terminal complement cascade and MAC formation, danicopan complements these therapies by controlling upstream alternative pathway activation that contributes to residual EVH.

Research evidence from recent clinical trials supports the efficacy of danicopan as an adjunct to C5 inhibitors, demonstrating improvements in hemoglobin levels, reduction in transfusion dependence, and stabilization of complement-mediated hemolysis. Its selective targeting of factor D also distinguishes it mechanistically from other complement inhibitors such as C3 or C5 blockers, offering a unique therapeutic strategy with a favorable side effect profile.

Pharmacological Actions

Selective inhibition of complement factor D, reducing activation of the alternative complement pathway.
Prevention of formation of C3 convertase enzyme complex, thereby controlling complement cascade amplification.
Mitigation of extravascular hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) by reducing opsonization of red blood cells.
Adjunctive action when combined with C5 inhibitors (ravulizumab or eculizumab) to provide comprehensive complement inhibition.
Potential immunomodulatory effects through selective complement system suppression without broad immunosuppression.
Reduction of hemolysis-related symptoms including anemia and transfusion requirements in PNH patients.
No significant inhibition of terminal complement complex formation when used alone, necessitating combination therapy.
Favorable pharmacokinetic profile allowing oral administration with consistent plasma levels.
Minimal systemic immunosuppression outside complement pathway, potentially preserving innate immune defenses.
May affect liver enzymes and lipid metabolism through secondary mechanisms related to complement regulation.
Does not interfere with complement activation pathways outside the alternative pathway, maintaining some immune functions.

Therapeutic Or Clinical Uses

Treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH) inadequately controlled by C5 inhibitors alone.
Adjunct therapy to ravulizumab (Ultomiris) or eculizumab (Soliris) for comprehensive complement inhibition.
Reduction of anemia and transfusion requirements in PNH patients experiencing clinically significant EVH.
Management of residual hemolytic activity not controlled by standard C5 inhibitor therapy.
Part of combination regimens aiming to improve hematological outcomes and quality of life in PNH.
Potential application in complement-mediated hemolytic disorders requiring alternative pathway modulation.
Treatment option for patients intolerant or unresponsive to C5 inhibitor monotherapy with residual hemolysis.
Therapy to reduce complement overactivation-related tissue damage in autoimmune hemolytic conditions.
Adjunctive use to maintain durable complement inhibition and reduce ongoing red cell destruction.
Clinical use under REMS program to manage risk of serious infections while optimizing efficacy.

Side Or Adverse Effects

Headache, the most commonly reported side effect occurring in 10% or more of patients.
Serious and potentially life-threatening infections, particularly from encapsulated bacteria such as Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B.
Elevated liver enzymes indicating hepatic stress or injury.
Increased blood lipid levels including cholesterol and triglycerides.
Potential allergic reactions or hypersensitivity responses.
Gastrointestinal disturbances, though less commonly reported.
Fatigue or malaise related to underlying disease or drug effects.
Injection site reactions are not applicable as drug is oral, minimizing local adverse events.
Risk of hemolytic crises if drug discontinuation occurs abruptly without medical supervision.
Possible drug interactions leading to increased side effect profiles when combined with substrates of BCRP or P-gp transporters.
Patients may experience flu-like symptoms related to complement modulation.
Monitoring for signs of infection such as fever, chills, rash, cough, or body aches is critical due to immunomodulatory effects.
Transient dizziness or nervous system effects reported in some patients.
Laboratory abnormalities including altered liver function tests during therapy.

Precautions

Ensure vaccination against Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B at least 2 weeks prior to initiating therapy unless immediate treatment is warranted.
Enrollment in the Voydeya REMS program is mandatory to manage infection risks and provide patient education.
Regular monitoring of liver function tests and blood lipid profiles during treatment.
Close clinical observation for signs of serious infections; patients should report symptoms promptly.
Not recommended for use in patients with severe hepatic impairment (Child-Pugh C).
Appropriate patient counseling regarding the importance of adherence to dosing to prevent hemolytic events.
Pregnant or breastfeeding women should avoid use due to lack of safety data; discuss risks and benefits thoroughly.
Avoid abrupt discontinuation to prevent acute hemolytic crises and anemia exacerbation.
Adjust dosing in patients receiving interacting medications, particularly substrates of BCRP and P-gp transporters.
Educate patients on carrying and presenting the Patient Safety Card to all healthcare providers.
Monitor for drug interactions that may increase plasma concentrations and adverse effects.
Consideration for immunocompromised status and potential diminished immune response.
Use caution in patients with active infection; withhold therapy until resolution.
Inform patients about the necessity to avoid exposure to infectious agents during treatment.

Warnings

Increased risk of serious and life-threatening infections from encapsulated bacteria.
Vaccination is required prior to therapy unless the risk of delay outweighs infection risk.
Voydeya has not demonstrated effectiveness as monotherapy and must be used as add-on to C5 inhibitors.
Not established as safe or effective in pediatric populations.
May increase liver enzymes and blood lipids; requires monitoring and possible discontinuation if abnormalities worsen.
Use in severe hepatic impairment is contraindicated due to increased toxicity risk.
Discontinuation without medical supervision may lead to severe hemolysis and anemia.
Patients have a prolonged infection risk window even after stopping therapy.
Timely recognition and treatment of infections are critical; delay may result in severe outcomes.
Interactions with substrates of BCRP and P-gp transporters may exacerbate side effects or toxicity.
Pregnancy and breastfeeding risks have not been definitively established; weigh risks versus benefits carefully.
The drug is only available through a restricted REMS program to ensure safe administration and monitoring.
Patients should be educated on signs and symptoms of infection and when to seek emergency medical attention.
Healthcare providers should consider all potential drug-drug and drug-disease interactions before prescribing.

Contraindication

Known hypersensitivity to danicopan or any component of the formulation.
Severe hepatic impairment classified as Child-Pugh C due to risk of toxicity and impaired drug clearance.
Current serious infection caused by encapsulated bacteria such as Neisseria meningitidis, Streptococcus pneumoniae, or Haemophilus influenzae type B.
Use as monotherapy without concomitant ravulizumab or eculizumab is contraindicated due to lack of efficacy.
Patients who have not received appropriate vaccinations against encapsulated bacteria prior to treatment initiation, unless immediate therapy is required and prophylactic antibiotics are administered.
Pediatric patients due to insufficient safety and efficacy data.
Concurrent use with other investigational complement inhibitors not recommended without clinical oversight.
Patients with uncontrolled infections or immunosuppression unrelated to PNH should avoid use until stabilization.
Use in pregnancy unless benefits clearly outweigh potential risks is contraindicated due to lack of safety data.
Known allergic reactions or anaphylactic reactions to related drugs or excipients.

Drug Interactions

May increase adverse effects of BCRP substrates such as methotrexate, irinotecan, and nitrofurantoin.
Dosage adjustments may be necessary for P-gp substrates like apixaban, colchicine, cyclosporine, dabigatran, and digoxin due to potential alterations in plasma drug concentrations.
Rosuvastatin dosage should not exceed 10 mg once daily when taken concomitantly with danicopan to avoid increased statin-related toxicity.
Potential interactions with CYP3A4 inhibitors or inducers may affect danicopan metabolism and plasma levels.
Concomitant immunosuppressants may modulate infection risk and require vigilant monitoring.
Interactions with other complement inhibitors may affect therapeutic efficacy and safety profile.
Danicopan may alter effects of anticoagulants and antiplatelet agents, warranting monitoring for bleeding complications.
Herbal supplements and over-the-counter medications that induce or inhibit CYP enzymes should be reported and monitored.
Concomitant use with strong inhibitors or inducers of P-glycoprotein transporter may necessitate dosing modifications.
Potential for additive hepatotoxicity with other hepatically metabolized drugs.
Avoid abrupt discontinuation of interacting drugs without medical advice to prevent adverse clinical consequences.
Drug interaction profiles necessitate thorough medication reconciliation before initiation and during therapy.
Patients should report all medications and supplements to healthcare providers to optimize management.
No significant interactions with vaccines noted, but vaccination timing is critical for infection prevention.

Preparations Of The Drug

Oral tablet, film-coated, containing active ingredient danicopan.
Available in 50 mg and 100 mg tablet strengths to allow flexible dosing.
Inactive ingredients include colloidal silicon dioxide, croscarmellose sodium, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate providing stability and tablet integrity.
Film coating components: polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide ensuring controlled dissolution and patient acceptability.
Packaged in original containers with clear labeling for dosage strength and administration instructions.
Supplied by Alexion Pharmaceuticals, Inc. under regulated manufacturing standards.
Distributed exclusively via the Voydeya REMS program to ensure patient safety and monitoring compliance.
Tablets are designed for oral administration with or without food to enhance patient adherence.
Storage recommendations include keeping at controlled room temperature between 20°C and 25°C (68°F to 77°F) and protected from moisture and light.
Keep out of reach of children to prevent accidental ingestion and overdose.
Each preparation batch undergoes quality control testing to ensure potency, purity, and consistency.
No injectable or alternative formulations currently available; oral tablets are sole route of administration.
Manufacturing adheres to FDA-approved guidelines and pharmacopoeial standards for selective immunosuppressants.
Patient safety cards accompany all drug dispensation to reinforce education on infection risks.
Prescription-only medication requiring healthcare provider supervision for dispensing and administration.